# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-ris...
- Reuters
U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Majo...
Johnson & Johnson announces $6.475 billion settlement for talc-related ovarian cancer lawsuits. Details on proposed resolut...
Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex T...
- Reuters
- Reuters